Pacira Pharmaceuticals, Inc. Release: Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement
9/20/2013 11:05:31 AM
PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results from a 200-patient study evaluating the benefits of EXPAREL® (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain management regimen in patients undergoing total knee arthroplasty (TKA), commonly known as total knee replacement. The findings show that patients treated with EXPAREL experienced better pain control with improved knee flexion and a shorter length of hospital stay compared to patients who received a femoral nerve block with a local anesthetic, the current standard of pain management for TKA. Additionally, the use of EXPAREL resulted in a substantial cost savings. The data were presented at the Marshall Steele 7th Annual Orthopedic and Spine Summit in San Antonio.
Help employers find you! Check out all the jobs and post your resume.
comments powered by